The biotech startup EraCal Therapeutics Ltd. develops a novel anti-obesity drug with superior efficacy and safety in zebrafish, mice, and rats compared to the standard of care (lorcaserin). Our zebrafish-based phenotypic platform enabled new target discovery and is applicable to other indications.

Cooperation possibilities

In vivo drug discovery, CNS active compounds, small molecule chemistry

Location
Facts & figures
  • Type of organization
    Private company
  • Year of foundation
    2018
  • Number of employees in Switzerland
    1-9
Key business